SEC Sues N.Y. Advisory Firm Owner and Friend for Insider Trading

The U.S. Securities and Exchange Commission sued a New York investment adviser over claims he made illegal trades ahead of Pfizer Inc. (PFE)’s planned acquisition of King Pharmaceuticals.

Tibor Klein made more than $300,000 for himself and his clients after learning confidential information about the planned merger in 2010, the SEC said in a complaint filed at U.S. District Court in Florida today. The agency also sued Michael Shechtman, a Florida-based stockbroker, who was allegedly tipped by Klein and reaped more than $100,000 in illicit gains.

Klein learned the non-public information about the impending merger in August 2010 from one of his clients -- an attorney who worked on matters for King Pharmaceuticals, the SEC said. He began purchasing large amounts of the company’s stock the next day the markets were open, according to the complaint.

That same day, Klein made six phone calls to Shechtman, who opened an options trading account, the SEC said. Two days later, Shechtman, who had never before traded in options, purchased 2,500 shares of King Pharmaceuticals stock and 300 call options in his personal account, as well as 2,400 shares in his wife’s retirement account, according to the agency.

When the acquisition plans were announced in October 2010, King Pharmaceuticals stock rose about 39 percent.

“As securities industry professionals, Klein and Shechtman clearly know the difference between legal and illegal trading,” Eric Bustillo, director of the SEC’s regional office in Miami, said in a statement. “Instead of playing by the rules, they chose to exploit non-public information for an easy payday, but they didn’t plan on getting caught by the SEC.”

The SEC is seeking disgorgement of illegal profits and a financial penalty.

Phone calls to attorneys for Klein and Shechtman were not immediately returned.

To contact the reporter on this story: Joshua Gallu in Washington at jgallu@bloomberg.net

To contact the editor responsible for this story: Maura Reynolds at mreynolds34@bloomberg.net

Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.